Skip to main content


1. P Bekker, D.J., G. Hamilton, S. Keshav, T. Schall: CCX282-B (Traficet-EN), an oral CCR9-specific
antagonist, induces high levels of remission in the open-label phase of PROTECT-1 clinical trial in
Crohn’s disease. ACG 2008, Orlando, P1078., 2008.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 443
444 Gastro Update 2009
2. A. Parikh, E.F., D. Solder, T. Wyant, V. Kadamby, T. Leach, C. Milch, I. Fox: Gastrointestinal selectivity
of vedolizumab (MLN0002), a humanized monoclonal antibody to alpha4beta7 integrin. Inflamm
Bowel Disease, 2008. 14(Suppl.): p. S18 (P-0025).
3. M. Regueiro, W.S., L Baidoo et al.: Infliximab for prevention of Crohn!s disease recurrance after ileal
resection. Am J Gastroenterol, 2008 p. Abstract 8.
4. D. Johnson, K.J., C. Chambers et al.: Pregnancy outcomes in women exposed to adalimumab: The otis
autoimmune disease pregnancy project. Am J Gastroenterol, 2008. Suppl. Abstr. 59.
5. D’Haens, G., et al.: Early combined immunosuppression or conventional management in patients with
newly diagnosed Crohn’s disease: an open randomised trial. Lancet, 2008. 371(9613): p. 660-7.
6. N. Baiod, N.B., N. Kaddache, A. Balamane, K. Belhocine, L. Kecili, N. Afredj, K. Layaida, L. Gamar,
N. Debzi, T.: Boucekkine Are initial localization and type of intestinal lesions predictors of anatomical
long term outcome in Crohn’s disease paients? UEGW 2008, Vienna, P0147, 2008.
7. D. K. L Chow ., J.J.Y.S., J. C. Y. Wu, W. Leung, K. K. F. Tsoi, R. W. L. Leong, F. K. L. Chan: Upper
gastrointestinal tract phenotype (L4) of Crohn’s disease is associated with early surgery and further
hospitalisation. UEGW 2008, Vienna, P0149., 2008.
8. A. Bourreille*, G.B., E. Mortier, M. Flamant, A. Plet, J. Galmiche, Y. Jacques: The IL-15/sIL-15Ra system
in Crohn’s disease, effect of infliximab therapy. . UEGW 2008, Vienna, OP181., 2008.
9. D. M. Weine, B.P.B., D. Poppers, E. Scherl: The role of serological markers in identifying infliximab
response in ulcerative colitis. ACG 2008, Orlando, P1081., 2008.
10. I. C. Solberg, I.L., J. Jahnsen, M. Vatn, B. Moum: Mucosal healing after initial treatment may be a
prognostic marker for long-term outcome in inflammatory bowel disease. UEGW 2008, Vienna,
OP070., 2008.
11. J. Colombel, X.H.: Endoscopic mucosal improvement in patients with active Crohn’s disease treated
with certolizumab pegol: First results of the MUSIC clinical trial ACG 2008, Orlando, P1107., 2008.
12. A. Papa, G.M., I. De Vitis, L. Guidi, G. Brandimarte, A. Tursi, W. Elisei, S. Guglielmo, I. Roberto, S. Ennas,
M. Bonizzi, G. Andrisani, C. Felice, A. Gasbarrini, G. Fedeli: Mucosal healing in ulcerative colitis
patients in long-term therapy with infliximab. . UEGW 2008, Vienna, p0784., 2008.
13. Sandborn W, R.P., Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, Lichtinger S, D’Haens G,
van der Woude C, Diamond R, Broussard D, Hegedus R, Colombel J: A randomized, double-blind,
controlled trial comparing IFX and IFX+AZA, to AZA in patients with CD naive to immunomodulators
and biologic therapy. Inflamm Bowel Disease, 2008. 14(Suppl.): p. S1 (O0001).
14. B. Feagan, J.M., T. Ponich et al.: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel
Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination with
Methotrexate for the Long-term Treatment of Crohn’s Disease (CD). Gastroenterology. 2008. 134(682c.).
15. Van Assche, G., et al.: Withdrawal of immunosuppression in Crohn’s disease treated with scheduled
infliximab maintenance: a randomized trial. Gastroenterology, 2008. 134(7): p. 1861-8.
16. W. Reinisch, R.L., E. Louis, M. Kron, A. Camez, P. F. Pollack: Effect of Concomitant Steroid or
Immunosuppressant Treatment on Adalimumab Response in Patients with Crohn’s Disease: Results
from the CARE Study. ACG 2008, Orlando, P1068., 2008.
17. S. Vermeire, P.R., G. D’Haens, J. Colombel, K. Mitchev, A. Raedler, R. Fedorak, S. Lee, W. Sandborn,
M. Abreu: Impact of concomittant steroid or IMM use on the efficacy of CZP in patients with CD who
no longer responded to or who had hypersensitivity to infliximab (WELCOME study). . UEGW 2008,
Vienna, P807., 2008.
18. F. Schnitzler, H.F., M. Ferrante, M. Noman, G. Van Assche, I. Hoffman, S. Vermeire, and P. Rutgeerts:
Flexibility in Interval and Dosing of Infliximab Enables Maintained Response of Patients with Crohn’s
Gastro 2009.qxd 5/9/2009 1:42 PM Page 444
Gyógyszerek, therápia 445
Disease. DDW 2008, San Diego. W1220., 2008.
19. W. Sandborn, J.C., P. Rutgeerts, P. Pollack, J. Chao, P. Mulani: Benefits of adalimumab dosage adjustment
for patients with Crohn’s disease: An analysis of the CHARM study. Inflamm Bowel Disease, 2008.
14(Suppl.): p. S29 (P-0063).
20. S. Lichtinger, D.B., D. Wolf et al.: ADA is effective in patients with fistulizing CD who were primary
nonresponders to IFX treatment. ACG 2008, Orlando, P1065., 2008.
21. S Vermeire, M.A., G D’Haens et al.: Efficacy and safety of CZP in patients with active CD who previously
lost response or were intolerant to infliximab: Open-label induction results of the WELCOME study.
Inflamm Bowel Disease, 2008. 14(Suppl.): p. S30 (P-066).
22. S. Hanauer, S.S., O. Thomsen, G. Lichtenstein, R. Bloomfield, W. Sandborn: Analysis of predictors of
response maintenance to certolizumab pegol in patients with Crohn’s disease: A data from Precise 2.
Journal of Crohn ‘s and Colitis, 2008. 2(1): p. 6 (P005).
23. G Lichtenstein, R.C., B Feagan et al.: Safety of infliximab and other Crohn’s disease therapies: Treat
registry data with 24,575-years follow up. . ACG 2008, Orlando, P1116., 2008.
24. Shale, M., et al.: Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut, 2008. 57(12): p.
25. J. Colombel, R.P., W. Sandborn et al.: Safety of adalimumab in patients with Crohn’s disease: analysis
of global clinical trials. Inflamm Bowel Disease, 2008. 14(Suppl.): p. S25 (P-0049).
26. J Colombel, S.S., P. Rutgeerts et al.: Long term safety of certolizumab pegol in Crohn’s disease:
integrated safety findings on serious adverse events of special interest ACG 2008, Orlando, P1101., 2008.